Combination therapy of finerenone and empagliflozin led to a significantly greater reduction in the urinary albumin-to-creatinine ratio (UACR) compared to either drug alone in patients with chronic kidney disease (CKD) and Type 2 diabetes, according to results from the CONFIDENCE trial reported in the New England Journal of Medicine . The results suggest a potential for more rapid and effective kidney protection in this high-risk patient population.

UACR is a critical biomarker for assessing kidney function and detecting chronic kidney disease, especially in its early stages. Elevated UACR is often the first sign of kidney damage, even when estimated glomerular filtration rate (eGFR) is still normal. Detection of albuminuria is a hallmark of glomerular injury and endothelial dysfunc

See Full Page